[Prospects of use of the combined preparation logimax in patients with essential hypertension].
OBJECTIVE
To study the effectiveness and tolerance of a combined drug logimax in patients with essential hypertension (EH).


METHODS
The antihypertensive activity and safety of logimax was evaluated in 15 EH patients at week 10 of therapy.


RESULTS
Logimax has a good antihypertensive effect for 24 hours in 86.7% patients. This was evidenced by the lowered mean systolic and diastolic pressures shown during 24-hour monitoring. Logimax was well tolerated. There were no side effects in 73.3% of the patients.


CONCLUSIONS
The combined drug logimax is indicated for patients with EH as an antihypertensive agent to treat and prevent cardiovascular events.
Ol'binskaia
L I
LI
Khapaev
B A
BA
Zheleznykh
E A
EA
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D002121:Calcium Channel Blockers / Q000627:therapeutic use*; D003692:Delayed-Action Preparations; D004338:Drug Combinations; D015736:Felodipine / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D008297:Male; D008790:Metoprolol / Q000627:therapeutic use*; D008875:Middle Aged
D000319:Adrenergic beta-Antagonists; D000959:Antihypertensive Agents; D002121:Calcium Channel Blockers; D003692:Delayed-Action Preparations; D004338:Drug Combinations; D008790:Metoprolol; D015736:Felodipine